Bio Essence Q3 Swings to $150K Loss; Going Concern and Weak Controls Reaffirmed
BIOE has more than doubled off its 52-week low of $0.051.
Summary
Bio Essence posted a $150,458 net loss for Q3 2026 after a profitable first half, while repeating going-concern doubt, disclosing ineffective internal controls, and holding just $201,511 of cash against $1.65 million of current liabilities.
Key Events · Earnings and Guidance · BIOE
-
Q3 Swings to $150,458 Net Loss
Three-month revenue rose 85.0% to $253,020, but G&A jumped 268.9% to $298,286 (including $174,942 of new intangible amortization), producing a $150,458 net loss versus $12,998 of income in Q3 2025.
-
Nine-Month Profit, Revenue Up 270%
Nine-month revenue reached $1,548,268 versus $418,112, and net income was $324,992 versus a $132,890 loss, with gross profit of $928,775 (60.0% margin).
-
Going Concern Doubt Reaffirmed
Accumulated deficit of $9,228,081 and working capital deficit of $1,374,178 keep substantial doubt about the ability to continue as a going concern; management estimates $1.2 million of cash is needed for the next 12 months.
-
Controls Concluded Not Effective
Management concluded disclosure controls and internal control over financial reporting were not effective as of September 30, 2026.
Analysis · BIOE · Life Sciences
The nine-month picture looks strong — revenue of $1,548,268, up 270.3%, and net income of $324,992 versus a $132,890 loss a year ago — but the third quarter alone reversed: a $150,458 net loss against $12,998 of income in Q3 2025, as general and administrative expense jumped 268.9% to $298,286, largely from $174,942 of amortization on the newly acquired MediFlow software. Against that, the company still carries a $9,228,081 accumulated deficit and a $1,374,178 working capital deficit, holds only $201,511 of cash against $1,653,097 of current liabilities, and says it needs about $1.2 million for the next 12 months. Management repeats that these conditions raise substantial doubt about its ability to continue as a going concern, and both disclosure controls and internal control over financial reporting were concluded not effective. A further 10,000,000 shares (contractual $0.10 each) are owed to Zhituo only if the AI platform development is completed and accepted, with milestone dates running to December 15, 2026 — a real overhang if it lands.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 47.3% of the 1873 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.17%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BIOE was trading at $0.47 on OTC in the Life Sciences sector, with a market capitalization of approximately $25.3M. The 52-week trading range was $0.05 to $10.81. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.